Trials / Completed
CompletedNCT06983704
Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma
Evaluation of Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
To asess the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.
Detailed description
Recurrent pediatric glaucoma following Ahmed Glaucoma Valve (AGV) implantation presents a therapeutic challenge. This study evaluates the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | AGV plate | AGV plate using a 27-gauge needle |
| PROCEDURE | bevacizumab injection | subconjunctival injection of bevacizumab |
Timeline
- Start date
- 2024-02-09
- Primary completion
- 2025-02-08
- Completion
- 2025-02-15
- First posted
- 2025-05-21
- Last updated
- 2025-05-21
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06983704. Inclusion in this directory is not an endorsement.